News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,523 Results
Type
Article (39691)
Company Profile (247)
Press Release (657585)
Multimedia
Podcasts (46)
Webinars (12)
Section
Business (204220)
Career Advice (2008)
Deals (35432)
Drug Delivery (95)
Drug Development (81196)
Employer Resources (172)
FDA (16170)
Job Trends (14851)
News (345354)
Policy (32529)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2556)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49455)
ALS (85)
Alzheimer's disease (1366)
Antibody-drug conjugate (ADC) (113)
Approvals (16171)
Artificial intelligence (237)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11638)
BIOSECURE Act (18)
Biosimilars (103)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (259)
Cancer (2068)
Cardiovascular disease (165)
Career advice (1675)
Career pathing (29)
CAR-T (143)
Cell therapy (400)
Cervical cancer (19)
Clinical research (65943)
Collaboration (784)
Compensation (498)
Complete response letters (19)
COVID-19 (2596)
CRISPR (37)
C-suite (221)
Cystic fibrosis (100)
Data (2038)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (255)
Diagnostics (6349)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (117)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (89)
Earnings (86307)
Editorial (33)
Employer branding (21)
Employer resources (146)
Events (111908)
Executive appointments (679)
FDA (17331)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (710)
Gene editing (99)
Generative AI (19)
Gene therapy (283)
GLP-1 (694)
Government (4400)
Grass and pollen (4)
Guidances (50)
Healthcare (18843)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (106)
Indications (26)
Infectious disease (2735)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (90)
Interviews (312)
IPO (16502)
IRA (40)
Job creations (3629)
Job search strategy (1423)
Kidney cancer (9)
Labor market (35)
Layoffs (460)
Leadership (16)
Legal (7909)
Liver cancer (72)
Lung cancer (300)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (276)
MASH (62)
Medical device (13339)
Medtech (13344)
Mergers & acquisitions (19436)
Metabolic disorders (651)
Multiple sclerosis (73)
NASH (16)
Neurodegenerative disease (82)
Neuropsychiatric disorders (24)
Neuroscience (1865)
NextGen: Class of 2025 (6516)
Non-profit (4479)
Northern California (2513)
Now hiring (37)
Obesity (350)
Opinion (204)
Ovarian cancer (74)
Pain (80)
Pancreatic cancer (79)
Parkinson's disease (144)
Partnered (21)
Patents (217)
Patient recruitment (99)
Peanut (46)
People (57200)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20575)
Phase II (29030)
Phase III (21628)
Pipeline (1102)
Policy (125)
Postmarket research (2565)
Preclinical (8691)
Press Release (64)
Prostate cancer (97)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (368)
Real estate (5908)
Recruiting (65)
Regulatory (22198)
Reports (46)
Research institute (2323)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (41)
Schizophrenia (65)
Series A (124)
Series B (80)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2168)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (63)
Tariffs (19)
The Weekly (27)
United States (21829)
Vaccines (673)
Venture capitalists (37)
Weight loss (228)
Women's health (34)
Worklife (15)
Date
Today (106)
Last 7 days (454)
Last 30 days (2489)
Last 365 days (33081)
2025 (8956)
2024 (35253)
2023 (40104)
2022 (51215)
2021 (55762)
2020 (54128)
2019 (46560)
2018 (35033)
2017 (32134)
2016 (31505)
2015 (37571)
2014 (31336)
2013 (26362)
2012 (28586)
2011 (29276)
2010 (27344)
Location
Africa (722)
Alabama (52)
Alaska (7)
Arizona (228)
Arkansas (13)
Asia (37780)
Australia (6176)
California (5720)
Canada (1924)
China (486)
Colorado (250)
Connecticut (262)
Delaware (133)
Europe (81202)
Florida (851)
Georgia (200)
Idaho (57)
Illinois (506)
India (24)
Indiana (297)
Iowa (9)
Japan (147)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (846)
Massachusetts (4305)
Michigan (214)
Minnesota (377)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (58)
New Hampshire (62)
New Jersey (1641)
New Mexico (28)
New York (1639)
North Carolina (933)
North Dakota (7)
Northern California (2513)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1293)
Puerto Rico (11)
Rhode Island (29)
South America (1096)
South Carolina (19)
South Dakota (1)
Southern California (2168)
Tennessee (97)
Texas (851)
Utah (170)
Virginia (135)
Washington D.C. (59)
Washington State (527)
West Virginia (3)
Wisconsin (51)
697,523 Results for "immunogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
March 10, 2025
·
3 min read
Press Releases
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
March 6, 2025
·
8 min read
Press Releases
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
February 27, 2025
·
7 min read
Press Releases
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
December 9, 2024
·
2 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.
February 1, 2024
·
1 min read
Press Releases
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
December 12, 2024
·
3 min read
Deals
AbbVie Completes Acquisition of ImmunoGen
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
February 12, 2024
·
8 min read
Genetown
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
January 3, 2024
·
1 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.
December 20, 2023
·
2 min read
Lone Star Bio
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
May 14, 2024
·
9 min read
1 of 69,753
Next
